Table 2.
Evidence for systemic treatments in adults (39).
| Treatment | Type of Study | N | Objective Response Rate | Other Response Rate | Reference |
|---|---|---|---|---|---|
| Sulindac | Retrospective | 14 | 57% | - | [55] |
| Toremifene | Retrospective | 27 | 22% | 6-month PFS: 76% | [56] |
| Metotrexate-Vinblastina | phase II | 27 | 15% | 10-year PFS: 67% | [57] |
| liposomal Doxorubicin | Retrospective | 14 | 33% | - | [58] |
| Doxorubicin + dacarbazine | Retrospective | 12 | 50% | - | [59] |
| Imatinib 800 mg/d | phase II | 51 | 6% | 1-year PFS: 66% | [51] |
| Imatinib 800 mg/d | phase II | 37 | 6% | 6-month PFS: 65% | [60] |
| Imatinib 400 mg/d | phase II | 50 | 12% | 1-year PFS: 67% | [61] |
| Sunitinib | phase II | 19 | 26% | 1-year PFS: 80% | [62] |
| Sorafenib | Retrospective | 26 | 26% | - | [63] |
* PFS. Progression-free survival. Adapted Penel [39].